Acceleron制药

XLRN NASDAQ
47.33
+1.57
+3.43%
盘后: 47.33 0 0.00% 16:49 08/21 EDT
开盘
46.30
昨收
45.76
最高
47.37
最低
45.71
成交量
20.35万
成交均量(3M)
30.63万
52周最高
59.59
52周最低
37.01
换手率
0.39%
市值
25.01亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Acceleron制药 XLRN股票价格,Acceleron制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
展开 >

最近浏览

名称
价格
涨跌幅